Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies, Inc. (SIGA) is a commercial-stage pharmaceutical company whose news flow centers on its role in health security and orthopoxvirus antivirals. The company regularly issues press releases on its financial results, government contracts, regulatory milestones, and corporate developments, giving investors and observers insight into the performance and direction of the business.
A recurring theme in SIGA’s news is the commercial progress of its flagship antiviral medicine, TPOXX (tecovirimat). Company updates describe product revenues from oral and IV TPOXX, including deliveries to the U.S. Strategic National Stockpile and sales to the U.S. Department of Defense and international customers. Releases also discuss procurement orders, outstanding orders, and the mix of domestic and international product sales.
Regulatory and development milestones are another key news category. SIGA has reported authorizations and approvals of TPOXX in multiple jurisdictions, including approval in Japan under the name TEPOXX for orthopoxvirus-related indications. The company also announces modifications to its BARDA 19C contract that add funding for pediatric development and manufacturing activities, reflecting ongoing development work around TPOXX.
Quarterly and annual earnings releases provide detailed financial statements, highlighting product sales, total revenues, operating income or loss, and net income or loss. These updates often include commentary from management on business performance, health security priorities, and the status of government and international contracts.
In addition, SIGA’s news includes governance and capital allocation items, such as the declaration of special cash dividends and appointments to the board of directors. Together, these disclosures offer a view into SIGA’s financial results, strategic relationships with governments and public health agencies, and its continuing focus on TPOXX as a countermeasure against orthopoxvirus-related diseases.
SIGA Technologies, Inc. (SIGA) announced about $13 million in procurement orders for its antiviral drug, oral TPOXX (tecovirimat). This includes $11 million for initial orders from two new international jurisdictions and $2 million from a country in the Asia Pacific region under an existing contract. The orders are driven by increased inquiries related to the global monkeypox outbreak, with SIGA expected to deliver approximately $4 million within 45 days and the remaining $7 million in 2023. The FDA approved oral TPOXX in 2018 to treat smallpox, highlighting its relevance amidst recent health threats.
SIGA Technologies (SIGA) announced its CEO Phil Gomez and CSO Dennis Hruby will join a panel on June 23, 2022, at 12 PM ET to discuss monkeypox outbreaks in the U.K., EU, and U.S. The event, hosted by Alliance Global Partners, will feature representatives from Emergent Biosolutions and Tonix Pharmaceuticals.
SIGA's lead product, tecovirimat (TPOXX), was approved by the EMA in January 2022 for treating smallpox and monkeypox. Although authorized for smallpox in the U.S., it is not FDA-approved for monkeypox treatment.
SIGA Technologies (SIGA) has received FDA approval for the intravenous (IV) formulation of TPOXX to treat smallpox. This approval allows broader access for patients who cannot take oral medications. The oral formulation is already approved in the US, Canada, and Europe. TPOXX is recognized for its role in U.S. preparedness against biological threats, including smallpox and monkeypox. SIGA remains committed to enhancing public health security through effective countermeasures.
On May 12, 2022, SIGA Technologies, Inc. (SIGA) announced a contract from the U.S. Department of Defense for up to $7.5 million of oral TPOXX, with $3.6 million earmarked for 2022. SIGA is also collaborating with the DoD to develop TPOXX for Post Exposure Prophylaxis (PEP), supported by a $26 million contract. The FDA approved TPOXX in 2018 for smallpox treatment, with further approvals from Health Canada and the European Medicines Agency in 2021 and 2022, respectively. CEO Phil Gomez highlighted the partnership as a significant step in securing customers for TPOXX.
On May 5, 2022, SIGA Technologies reported significant progress with the first sale of intravenous TPOXX to the U.S. government under the 19C BARDA contract, generating $7 million in revenue. The company also secured a new contract in Asia Pacific for $3 million of oral TPOXX. Financially, total revenues reached $10.5 million in Q1 2022, compared to $4.8 million in Q1 2021. A special dividend of $0.45 per share has been declared, payable on June 2, 2022. Additionally, the company repurchased 1 million shares for $6.6 million, reflecting confidence in continued growth.
SIGA Technologies, Inc. (SIGA) has declared a special dividend of $0.45 per share on its common stock. This dividend will be payable on June 2, 2022, to shareholders recorded by the end of business on May 17, 2022. CEO Phil Gomez stated that this decision reflects the company's strong financial performance in 2020 and 2021, along with confidence in future prospects. SIGA specializes in countermeasures for health security, notably its lead product TPOXX, an antiviral for smallpox, with significant orders from the U.S. government amounting to approximately $705 million.
SIGA Technologies, Inc. (SIGA) announced a business update webcast scheduled for May 5, 2022, at 4:30 P.M. ET. The call will feature key executives including CEO Dr. Phil Gomez and CFO Daniel Luckshire. SIGA focuses on health security, with its primary product being TPOXX, an antiviral drug for smallpox, backed by approximately $705 million in U.S. government procurement. The oral formulation of TPOXX received FDA approval in 2018, while the EMA approved it in January 2022. More details are available on SIGA's website.
SIGA Technologies, Inc. (SIGA) reported robust financial results for 2021, achieving $133.7 million in total revenues, an increase from $89.1 million in 2020. The company delivered approximately $113 million of its oral TPOXX® to the U.S. government, amid significant supply chain challenges. International product sales rose to $13 million, compared to $2 million in 2020. SIGA also repurchased 3.8 million shares, representing about 5% of shares outstanding. With EMA approval for oral Tecovirimat in early 2022, SIGA is well-positioned for further growth.
SIGA Technologies, Inc. (SIGA) has initiated a clinical program to expand the FDA label for TPOXX® to include Post-Exposure Prophylaxis (PEP) for smallpox. The first study will compare immune responses to the Jynneos vaccine in participants receiving TPOXX. A second study aims to develop a safety dataset for extending TPOXX's dosing from 14 to 28 days. The research is supported by a $26 million R&D contract with the U.S. Department of Defense, highlighting concerns about smallpox as a potential bioweapon. TPOXX was previously approved for treating smallpox in July 2018.
SIGA Technologies, Inc. (SIGA) will host a webcast and conference call to provide a business update on March 3, 2022, at 4:30 PM ET. Participating will be CEO Dr. Phil Gomez and CFO Daniel Luckshire. The call can be accessed via a dedicated phone line or through a live webcast available on the company’s website. SIGA focuses on the health security market, with its lead product TPOXX® approved for treating human smallpox and various pox diseases. The company highlights the importance of TPOXX in biodefense and preparedness.